BBOT vs NOC · $610.4M cap vs P/E 17, rev $41.95B
BridgeBio Oncology Therapeutics, Inc. (BBOT) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
BridgeBio Oncology Therapeutics, Inc. (BBOT) is a biotechnology company listed on NASDAQ.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
BBOT does not have a complete income-statement cache yet.
Latest reported NOC revenue for 2025-12-31 was $41.95B. Net income was $4.18B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
BBOT currently screens at market cap $610.4M. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the BBOT and NOC stock pages for the full models.
Not investment advice.